Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8829487 | 0.88 | HTR2A (0.41) | HTR2AOPRM1KMT2AOPRD1OPRK1 | |
| SCHEMBL8829484 | 0.88 | HTR2A (0.41) | HTR2AOPRM1KMT2AOPRD1OPRK1 | |
| SCHEMBL8829485 | 0.88 | HTR2A (0.41) | HTR2AOPRM1KMT2AOPRD1OPRK1 | |
| SCHEMBL14101489 | 0.76 | HTR2A (0.37) | HTR2AKMT2A | |
| SCHEMBL15717673 | 0.76 | HTR2A (0.41) | HTR2AOPRM1KMT2A | |
| SCHEMBL15717672 | 0.76 | HTR2A (0.41) | HTR2AOPRM1KMT2A | |
| SCHEMBL3369554 | 0.76 | HTR2A (0.37) | HTR2AKMT2A | |
| SCHEMBL15717675 | 0.76 | HTR2A (0.41) | HTR2AOPRM1KMT2A | |
| SCHEMBL28546015 | 0.74 | HTR2A (0.42) | HTR2AOPRM1KMT2A | |
| SCHEMBL15630885 | 0.72 | HTR2A (0.41) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853572-A1 | FLUORINATED PHNO AND ANALOGS THEREOF | Clera Inc. (CA) | 2007-11-14 | — | — | EP | claimed |
| US-20070155736-A1 | FLUORINATED PHNO AND ANALOGUES THEREOF | CLARA INC. (CA) | 2007-07-05 | — | — | US | claimed |
| WO-2006084368-A1 | FLUORINATED PHNO AND ANALOGS THEREOF | CLERA INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| CN-102223900-A | Imaging ligands | GEN ELECTRIC | 2011-10-19 | — | — | CN | disclosed |
| US-20110217234-A1 | IMAGING LIGANDS | GENERAL ELECTRIC COMPANY | 2011-09-08 | — | — | US | disclosed |
| US-20080181848-A1 | METHOD TO DETECT DOPAMINE RECEPTORS IN THE FUNCTIONAL D2HIGH STATE | SEEMAN PHILIP | 2008-07-31 | — | — | US | disclosed |
| EP-1853572-A1 | FLUORINATED PHNO AND ANALOGS THEREOF | Clera Inc. (CA) | 2007-11-14 | — | — | EP | disclosed |
| EP-1812081-A1 | METHOD TO DETECT DOPAMINE RECEPTORS IN THE FUNCTIONAL D2HIGH STATE | Clera Inc. (CA) | 2007-08-01 | — | — | EP | disclosed |
| US-20070155736-A1 | FLUORINATED PHNO AND ANALOGUES THEREOF | CLARA INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070128107-A1 | METHOD TO DETECT DOPAMINE RECEPTORS IN THE FUNCTIONAL D2HIGH STATE | CLERA INC. (CA) | 2007-06-07 | — | — | US | disclosed |
| WO-2006084368-A1 | FLUORINATED PHNO AND ANALOGS THEREOF | CLERA INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006047861-A1 | METHOD TO DETECT DOPAMINE RECEPTORS IN THE FUNCTIONAL D2HIGH STATE | CLERA INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217234-A1 | IMAGING LIGANDS | DRD2, SLC6A3, DRD3 | HTR2A 36/4885OPRM1 118/4885KMT2A 3631/4885 |
| US-20070155736-A1 | FLUORINATED PHNO AND ANALOGUES THEREOF | DBH, SLC6A3, PDE7A | HTR2A 80/4885OPRM1 57/4885KMT2A 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.